In conclusion, the data shown here highlight the effective use in ALS of recombinant AAV vectors for intraspinal transgene delivery and point to the upregulation of VDAC1 as a possible therapeutic molecule to restore proper mitochondrial functioning in the ALS-affected tissues. Here, VDAC1 is linked to amyotrophic lateral sclerosis.